
1/ Why have anti-GITR agonists, despite strong preclinical activity, shown limited clinical success? Our new study in @NatureCancer points to Fc receptor pathways as a key missing piece. Led by the amazing @AvYahel, Natasha Barth nature.com/articles/s43018-0…























